Rare disease biotech Rallybio cuts 19 staffers and sheds partnered preclinical programs Rallybio is laying off close to half of its employees and seeking “alternative options” for its preclinical programs as it gets ready to put the two lead candidates into Phase II. Facing a harsh funding environment, Rallybio joins a wave of biotechs doubling down on their most advanced assets and shedding the rest to save costs. In total, it is cutting 19 employees, or 45% of the workforce. In its case, the New Haven, CT-based biotech is betting on a pair of potential rare autoimmune disease treatments: RLYB212, an anti-HPA-1a antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB116, a once-weekly, low volume subcutaneously injected C5 inhibitor that will be tested for complement-mediated diseases. It expects to start a mid-stage trial for RLYB212 in pregnant women and come up with a development plan for RLYB116 at an optimized dose in the second half of the year. Unlock this article instantly by becoming a free subscriber. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
This content was originally published here.
